MULTERA

Next-Generation Molecular Diagnostic Platform Powering Clinical and AI Infrastructure

MultiPlexa

Enabling early and timely disease detection
Ultra-multiplexity and ultra-sensitivity
Cost-effective, convenient and fully accessible solution

Ultra Throughput

100+ multiplexing unlocks maximum diagnostic throughput

Accessibility

Engineered for standard benchtop
No centralized laboratory required

Timely

Rapid results empowering clinicians when personalized treatment decisions matter

Advancing Life Sciences

MultiPlexa provides a complete, end-to-end IVD ecosystem combining ultra-high sensitivity and cost-effective accessibility for next-generation disease detection.

MultiPlexa Platform
Rapid-cycling molecular diagnostic analyser engineered for the clinic, equiped with automated data processing and reporting

MultiPlexa Universal Kits
Versatile reagents applicable for different scenarios

Clinical Test Kits
Sepsis
Prenatal
Multi-Cancer Early Detection (MCED)

Contact us for custom assay

Workflow in Action

We present a dynamic overview of our MultiPlexa Platform. From DNA partitioning to PCR cycles and target detection.

ABOUT MULTERA

Bridging the gap between ultra-multiplex screening and rapid diagnostic decision-making

Founded in 2025, Multera Limited is dedicated to developing MultiPlexa, a next-generation genomic intelligence platform designed to enable rapid, high-resolution, ultra-multiplex molecular analysis in decentralized clinical settings.

MultiPlexa directly responds to societal needs for earlier disease detection, accessible precision diagnostics, and resilient healthcare infrastructure. By lowering the barrier to high-resolution genomic analysis, the platform extends advanced molecular diagnostics beyond major metropolitan centres. In oncology and prenatal care, earlier and more comprehensive detection improves patient outcomes and reduces long-term healthcare burden. In critical disease like sepsis, earlier identification saves patients’ life.